NDAORALTABLETPriority Review
Approved
Jul 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOLINASE (tolazamide) is an oral sulfonylurea antidiabetic agent approved in 1966 for the treatment of type 2 diabetes mellitus. It lowers blood glucose by stimulating insulin secretion from pancreatic beta cells. This first-generation oral hypoglycemic has largely been superseded by newer agents with improved safety and efficacy profiles.
LOE Approaching
Minimal commercial activity; team size and investment likely contracted significantly as product approaches end-of-life in a crowded diabetes market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TOLINASE offers minimal career progression opportunity given the product's mature lifecycle, negligible market share, and zero linked job openings. Assignment to this brand typically indicates a role managing declining revenues or transitioning to higher-priority products within the diabetes portfolio.
Field Sales RepresentativeBrand Manager
Worked on TOLINASE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.